Endo Nph Bbi Enteral Nutrition Hyperglycemia

---
name: endo-nph-bbi-enteral-nutrition-hyperglycemia
description: Recommends neutral protamine Hagedorn–based or basal bolus insulin regimens for managing hyperglycemia in adults receiving enteral nutrition with diabetes-specific or nonspecific formulations during noncritical illness. Trigger phrases include hyperglycemia noted during enteral nutrition therapy, hyperglycemia on tube feeding, or enteral nutrition–associated hyperglycemia in a patient on PEG or NG tube.
---

# Use NPH-based or basal bolus insulin regimens for enteral nutrition–associated hyperglycemia

## STEP 1 — Gather Information
- Confirm patient is receiving enteral nutrition (PEG, NG, orogastric tube).
- Document current blood glucose (point-of-care) and trend over past 24 h.
- Review diabetes history (known diabetes, HbA1c, home insulin regimen).
- Note enteral formulation (diabetes‑specific vs standard) and feeding schedule (continuous, bolus, cyclic).
- Assess renal function and risk factors for hypoglycemia.
Action: Proceed to step 2 if hyperglycemia (BG >180 mg/dL on two checks or persistent >140 mg/dL) is noted during feeding.

## STEP 2 — Rule In / Rule Out
- If hyperglycemia is documented during enteral nutrition therapy (e.g., two POC‑BG >180 mg/dL or persistent >140 mg/dL), rule in enteral nutrition–associated hyperglycemia and proceed to step 3.
- If no hyperglycemia, rule out enteral nutrition–associated hyperglycemia; continue routine glucose monitoring and consider other causes.
Action: If ruled in, go to step 3; if ruled out, maintain standard monitoring and reassess if clinical status changes.

## STEP 3 — Classify or Stratify
- Classify patient as either already on a scheduled insulin regimen (basal or basal bolus) at home or insulin‑naive.
- If already on scheduled insulin, assess current dose and timing relative to feeds.
- If insulin‑naive, note absence of prior insulin.
Action: Based on classification, proceed to step 4 for regimen selection.

## STEP 4 — Decide
- For patients already on scheduled insulin, continue or adjust to an NPH‑based regimen (e.g., NPH 0.1–0.2 units/kg at bedtime) or basal bolus insulin (basal glargine/detemir plus prandial rapid‑acting) matched to enteral carbohydrate load.
- For insulin‑naive patients, initiate an NPH‑based regimen (e.g., NPH 0.1–0.2 units/kg at bedtime) or basal bolus insulin with prandial dosing guided by carbohydrate content of feeds.
- In all cases, start with conservative doses and adjust based on q6h POC‑BG, targeting 100–180 mg/dL.
Action: Implement selected insulin regimen and order frequent glucose monitoring.

## Clinical Guardrails / Mimics / Pitfalls
- Avoid sliding scale insulin alone; it is ineffective and increases hypoglycemia risk.
- Do not use NPH if feeding is intermittent without consistent carbohydrate coverage; consider basal bolus instead.
- Monitor for hypoglycemia, especially when feeds are held or interrupted; hold insulin if BG <70 mg/dL.
- Consider renal insufficiency; reduce insulin dose if eGFR <30 mL/min.
- Do not ignore hyperglycemia during corticosteroid co‑therapy; may need higher doses.
- Avoid rapid uptitration; increase dose by no more than 10–20% every 24 h to prevent hypoglycemia.

## Concrete Clinical Example
A 68‑year‑old woman with type 2 diabetes on home metformin is admitted for pneumonia and placed on a PEG tube receiving a standard enteral formula at 60 mL/hr. Six hours after initiation, two POC‑BG readings are 192 and 205 mg/dL. She has no prior insulin. She is classified as insulin‑naive. An NPH‑based regimen is started with NPH 10 units at bedtime (based on 0.15 units/kg). Glucose is checked q6h; after 12 h, pre‑lunch BG is 148 mg/dL and NPH is increased to 12 units. She remains hyperglycemic; basal bolus insulin is added with glargine 10 units at bedtime and aspart 4 units before each bolus feed.

**Source:** Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278